You are here: Industry Insights > Tecentriq

News List

Genentech gets FDA approval for Tecentriq, Avastin combo for HCC pharmaceutical-business-review
June 03, 2020
Genentech has secured approval from the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).
NICE u-turn backs Roche's Tecentriq for small-cell lung cancer pharmatimes
May 29, 2020
A combination of Roche's Tecentriq (atezolizumab), carboplatin and etoposide has now been recommended as an NHS-funded option for untreated extensive-stage small-cell lung cancer (ES-SCLC), following an earlier rejection by cost regulators.
NICE u-turn backs Roche's Tecentriq for triple negative breast cancer pharmatimes
May 27, 2020
NICE is now backing NHS use of Tecentriq (atezolizumab) with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer, following an “improved offer” from drugmaker Roche.
FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCL pharmaceutical-business-review
May 21, 2020
Genentech, a member of the Roche Group, announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC).
New US nod for Roche's Tecentriq in NSCLC pharmatimes
May 20, 2020
The US Food and Drug Administration has approved Roche's Tecentriq (atezolizumab) as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression ...
Another Anti-PD-L(1) Monoclonal Antibody Filed the IND Application in China to Join the 40+ Applicants! Sales of Keytruda to Rank Second in the World in 2019 PharmaSources/1°C
November 14, 2019
MSD released the Q3 financial report on Oct. 29, 2019. Its figures, especially the figures of its oncology business, were no longer shining, with keywords including Keytruda, Gardasil 9, and China.
EC approves Roche’s Tecentriq combination to treat breast cancer pharmaceutical-technology
September 03, 2019
Roche has gained approval from the European Commission (EC) for Tecentriq (atezolizumab) with chemotherapy (Abraxane) to treat patients with unresectable locally advanced or...
Roche's Tecentriq grabs I-O's first European OK for triple-negative breast cancer fiercepharma
September 02, 2019
Back in March, Roche’s Tecentriq led its class of immuno-oncology drugs into the triple-negative breast cancer arena (TNBC), picking up the first FDA OK in the tough-to-treat disease. Now, it’s done the same across the pond.
Roche’s Tecentriq/Abraxane Combo for TNBC Approved by EU contractpharma
August 30, 2019
The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer.
Roche’s ipatasertib combo shows early promise in triple-negative breast cancer pharmatimes
April 04, 2019
Roche has announced results from a Phase Ib trial assessing its AKT-inhibitor ipatasertib, Tecentriq (atezolizumab) and chemotherapy in triple-negative breast cancer (TNBC), showing a 73% overall response rate irrespective of PD-L1 status.

Previous page 1 2 3 4 5 6 7 Next page